

Arianna Sartori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4558834/publications.pdf>

Version: 2024-02-01

37
papers

474
citations

759233

12
h-index

752698

20
g-index

37
all docs

37
docs citations

37
times ranked

815
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical neurophysiology and cerebrospinal liquor analysis to detect Guillain-Barré syndrome and polyneuritis cranialis in COVID-19 patients: A case series. <i>Journal of Medical Virology</i> , 2021, 93, 766-774.	5.0	74
2	Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1263-1272.	3.0	36
3	Epidemiology of amyotrophic lateral sclerosis in Friuli-Venezia Giulia, North-Eastern Italy, 2002-2014: a retrospective population-based study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 90-99.	1.7	35
4	Predictors of diagnostic delay in amyotrophic lateral sclerosis: a cohort study based on administrative and electronic medical records data. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2019, 20, 176-185.	1.7	34
5	Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. <i>Journal of Neurology</i> , 2017, 264, 1068-1075.	3.6	25
6	Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 58, 103424.	2.0	25
7	The Incidence of Amyotrophic Lateral Sclerosis in Friuli Venezia Giulia, Italy, from 2002 to 2009: A Retrospective Population-Based Study. <i>Neuroepidemiology</i> , 2013, 41, 54-61.	2.3	20
8	Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. <i>Immunological Investigations</i> , 2018, 47, 135-145.	2.0	18
9	Comfortable walking speed and energy cost of locomotion in patients with multiple sclerosis. <i>European Journal of Applied Physiology</i> , 2020, 120, 551-566.	2.5	18
10	Teriflunomide: a novel oral treatment for relapsing multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1019-1027.	1.8	16
11	Cerebrospinal fluid and serum interleukins 6 and 8 during the acute and recovery phase in COVID-19 neuropathy patients. <i>Journal of Medical Virology</i> , 2021, 93, 5432-5437.	5.0	15
12	Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. <i>Journal of Neuroimmunology</i> , 2021, 356, 577586.	2.3	15
13	A real-world study of alemtuzumab in a cohort of Italian patients. <i>European Journal of Neurology</i> , 2022, 29, 257-266.	3.3	15
14	Early Recovery of Aphasia through Thrombolysis: The Significance of Spontaneous Speech. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1937-1948.	1.6	13
15	Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy. <i>Multiple Sclerosis Journal</i> , 2022, 28, 93-101.	3.0	13
16	ASL MRI and 18F-FDG-PET in autoimmune limbic encephalitis: clues from two paradigmatic cases. <i>Neurological Sciences</i> , 2021, 42, 3423-3425.	1.9	12
17	Prevalence of hypohydration and its association with stroke severity and independence outcomes in acute ischemic stroke patients. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 281-286.	1.5	10
18	Effects of a cooling vest with sham condition on walking capacity in heat-sensitive people with Multiple Sclerosis. <i>European Journal of Applied Physiology</i> , 2020, 120, 2467-2476.	2.5	8

#	ARTICLE	IF	CITATIONS
19	Early putamen hypertrophy and ongoing hippocampus atrophy predict cognitive performance in the first ten years of relapsing-remitting multiple sclerosis. <i>Neurological Sciences</i> , 2020, 41, 2893-2904.	1.9	8
20	How far away from having an effective treatment option for progressive multiple sclerosis are we?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 953-955.	1.8	7
21	Thrombolysisâ€™ benefits on early post-stroke language recovery in aphasia patients. <i>Journal of Clinical Neuroscience</i> , 2019, 70, 92-95.	1.5	7
22	Can We Speak of Lack of Habituation in Visual Snow?. <i>Headache</i> , 2016, 56, 1517-1518.	3.9	6
23	Motor neuron disease as a treatment responsive paraneoplastic neurological syndrome in patient with small cell lung cancer, anti-Hu antibodies and limbic encephalitis. <i>Journal of the Neurological Sciences</i> , 2019, 400, 158-159.	0.6	6
24	Efficacy of rituximab on seizure control and cognitive symptoms in leucineâ€™rich, gliomaâ€™inactivated 1 (LGI1) limbic encephalitis: a highâ€™density electroencephalography case study. <i>Epileptic Disorders</i> , 2020, 22, 678-682.	1.3	6
25	Hiccups, severe vomiting and longitudinally extensive transverse myelitis in a patient with prostatic adenocarcinoma and Aquaporin-4 antibodies. <i>Journal of Neuroimmunology</i> , 2021, 352, 577488.	2.3	5
26	Avoiding misdiagnosis: cystic calcified brain metastases of uterine cervical cancer mimicking neurocysticercosis. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016217952.	0.5	4
27	Acute isolated aphasia as a challenging symptom in the emergency setting: Predictors of epileptic mimic versus ischemic stroke. <i>Journal of Clinical Neuroscience</i> , 2019, 67, 129-133.	1.5	4
28	First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102059.	2.0	4
29	Lymphopenia during treatment with dimethyl fumarate in patients with multiple sclerosis: Prevalence, predicting factors and clinical outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103357.	2.0	4
30	¹²³Iâ€™Metaiodobenzylguanidine</sup> Myocardial Scintigraphy in Discriminating Degenerative Parkinsonisms. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 717-724.	1.5	3
31	Unveiling the relationship between autonomic involvement, fatigue, and cognitive dysfunction in early relapsingâ€™remitting multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 4281-4287.	1.9	3
32	Nabiximols and botulinum toxin injections for patients with multiple sclerosis: efficacy on spasticity and spasms in a single-centre experience. <i>Neurological Sciences</i> , 2021, 42, 5037-5043.	1.9	2
33	Isolated aphasic status epilepticus: CT perfusion, SPECT and EEG reveal neurovascular coupling and support the differential diagnosis. <i>Epileptic Disorders</i> , 2022, 24, 549-554.	1.3	2
34	The reappearance of hemiplegic cluster headaches: A case report and review of the literature. <i>Clinical Neurology and Neurosurgery</i> , 2017, 158, 12-14.	1.4	1
35	Challenges in the Diagnosis and Treatment of Neuromyelitis Optica Spectrum Disorders: A Case Report With a Brief Review of Literature. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2018, 6, 232470961880950.	0.6	0
36	Comment on â€™Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19â€™. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2020, 81, 166.	2.0	0

#	ARTICLE	IF	CITATIONS
37	Paraneoplastic neurological syndromes associated with non-Hodgkin lymphoma: a case series. <i>Neurological Sciences</i> , 2022, 43, 2077-2079.	1.9	0